Handling and standardization of EBUS needle aspiration in NSCLC patients: The value of the cell block, a monoinstitutional experience

Background Lung cancer is the main cause of cancer‐related death worldwide, and 85% of all lung tumors are non‐small cell lung cancers (NSCLC). More than 60% of all lung tumors are diagnosed at an advanced stage, leading to poor prognosis. Given the growing demand for NSCLC profiling for selection of the most appropriate therapy, the acquisition of adequate tumor samples has become increasingly crucial, mostly in advanced NSCLC patients due to old age and/or comorbidities. Being a mini‐invasive sampling technique, endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) represents a valuable alternative to traditional transthoracic or surgical sampling in these patients, and perfoming cell block (CB) could be crucial to maximize the potential biological information. The aim of this study is to describe a monoinstitutional interprofessional experience in handling EBUS‐TBNA and CB in 464 patients. METHODS We retrospectively collected all the consecutive CBs obtained from EBUS TBNA performed between 2014 and 2021 on the lung lesions or mediastinal lymph nodes. All the CBs were handled in a standardized method. RESULTS A total of 95.5% (448/464 samples) of adequacy for site and 92.6% (430/464) of adequacy for diagnosis were observed. Moreover, in the adenocarcinoma histotype, ALK, ROS1 and tumor proportion score (TPS) PD‐L1 assessment by IHC was possible in 96% (140/146) of cases, and molecular profile was obtained in 93.8% (137/146) of cases. In the squamous cell carcinoma histotype, TPS PD‐L1 assessment was possible in 81% (13/16) of cases. All four CB results obtained from carcinoma NOS were adequate for ALK, ROS1 and PD‐L1 assessment and molecular profiling. All 39 metastatic samples from extra‐pulmonary primary were adequate for immunohistochemical characterization and molecular profiling. Finally, reporting of the tumor sample adequacy to the clinicians took a median time of about 30 h (range: 24–80 h). Conclusion Careful cytological smear management together with the handling and standardization of CB obtained from EBUS‐TBNA could represent an effective method to increase the adequacy of the tumor specimen for both diagnosis and molecular profile. In advanced NSCLC patients, a less invasive procedure such as EBUS‐TBNA allows a more accurate acquisition of samples. Careful cytological smear management together with the handling and standardization of CB obtained from EBUS‐TBNA could represent an effective method to increase the adequa